Show simple item record

dc.contributor.authorCarroll, K Ben
dc.contributor.authorMoussalli, Hen
dc.contributor.authorBrown, Den
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-21T12:27:08Z
dc.date.available2010-07-21T12:27:08Z
dc.date.issued1983-04
dc.identifier.citationA comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent. 1983, 77 (2):171-8 Br J Dis Chesten
dc.identifier.issn0007-0971
dc.identifier.pmid6307334
dc.identifier.doi10.1016/0007-0971(83)90024-4
dc.identifier.urihttp://hdl.handle.net/10541/108073
dc.description.abstractSixty-eight patients with inoperable but 'limited' stage small-cell carcinoma of the bronchus were treated with two different chemotherapy regimens. Thirty-four patients received methotrexate, cyclophosphamide, procarbazine and vincristine in standard dose over a 2-year schedule. Thirty-four patients received cyclophosphamide alone over a period of 3 months. The groups were evenly balanced with respect to clinical details which are fully described. Toxicity was acceptable. The median actual survival for the whole group was 11 months, the 1-year, 2-year and 4-year survival being 48%, 30% and 1.5% respectively. There was no statistically significant difference in survival between those classified as responders and those as non-responders, nor between the groups treated with the two different regimens. There was a high local recurrence rate.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma, Bronchogenic
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshCyclophosphamide
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMethotrexate
dc.subject.meshMiddle Aged
dc.subject.meshProcarbazine
dc.subject.meshVincristine
dc.titleA comparison between a single agent short course chemotherapy regimen and a quadruple prolonged course regimen for small-cell bronchogenic carcinoma of limited extent.en
dc.typeArticleen
dc.contributor.departmentRegional Cardiothoracic Unit, Wythenshawe Hospital, Southmoore Road, Manchester 23 UK.en
dc.identifier.journalBritish Journal of Diseases of the Chesten
html.description.abstractSixty-eight patients with inoperable but 'limited' stage small-cell carcinoma of the bronchus were treated with two different chemotherapy regimens. Thirty-four patients received methotrexate, cyclophosphamide, procarbazine and vincristine in standard dose over a 2-year schedule. Thirty-four patients received cyclophosphamide alone over a period of 3 months. The groups were evenly balanced with respect to clinical details which are fully described. Toxicity was acceptable. The median actual survival for the whole group was 11 months, the 1-year, 2-year and 4-year survival being 48%, 30% and 1.5% respectively. There was no statistically significant difference in survival between those classified as responders and those as non-responders, nor between the groups treated with the two different regimens. There was a high local recurrence rate.


Files in this item

This item appears in the following Collection(s)

Show simple item record